Semaglutide
60 articles on Semaglutide, researched and written by the Shotlee Editorial Team from primary sources.
What's the Deal with Peptides? The Hyped Market Under FDA Review
An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.
8 min read
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.
8 min read
Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials
Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.
7 min read
Truth About Mounjaro Jowls: Rosie O'Donnell's Facelift That Can't Hide Weight Loss
Rapid weight loss on GLP-1 medications often leads to skin laxity because the body loses subcutaneous fat faster than collagen and elastin can regenerate. This biological lag creates visible sagging, particularly in areas with high elasticity like the jawline and neck.
6 min read
New Yorkers Are Ordering Peptides Like Takeout – And California Trim Clinic Is Behind It
New York City is experiencing a surge in peptide therapy requests via telehealth platforms. This article explores the most popular compounds, safety protocols, and how to track results effectively.
8 min read
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.
8 min read
Peptides Get Their Regulatory Close-Up at FDA Review
The FDA is convening a panel to review regulations on popular injectable peptides. Learn about safety concerns, clinical evidence gaps, and what this means for patient access to peptide therapy.
8 min read
Semaglutide Offers Kidney Protection in Type 2 Diabetes and CKD, JACC Study Confirms
New findings from a major subgroup analysis of the FLOW trial, published in the Journal of the American College of Cardiology, demonstrate that semaglutide offers significant and consistent kidney protection for adults living with type 2 diabetes and chronic kidney disease (CKD). This benefit extends to individuals regardless of their existing heart disease, heart failure, or elevated cardiovascular risk.
9 min read
How Iconic Philly Food Brands Are Adapting to Calorie-Conscious Consumers
Philadelphia's iconic food brands are evolving, introducing high-protein and functional food options to cater to the growing number of calorie-conscious consumers, influenced by trends like GLP-1 medications and a desire for healthier choices.
8 min read
Semaglutide for Weight Loss in Adults Over 65: New Study Findings
A recent analysis of the STEP trials reveals that semaglutide, the active ingredient in popular medications like Ozempic and Wegovy, offers significant weight loss and health benefits for adults over 65 with obesity, with a safety profile comparable to younger populations.
8 min read
Fat Jabs Slash Alcohol-Related Hospitalisations by More Than a Quarter
Recent analysis indicates that GLP-1 weight loss medications significantly reduce the risk of alcohol-related hospital admissions by approximately 26 percent compared to other diabetes treatments.
8 min read
Doctors Warn a New GLP-1 Finding May Raise Your Risk of Smell Loss
Researchers analyzed nearly 877,000 patients and found a significant link between GLP-1 receptor agonists and sensory disturbances.
8 min read
I Lost 5 Stone on Mounjaro — But Now I’ve Had Enough
Natalie Lavergne transformed her health and lost 5 stone using Mounjaro, but now plans to switch to the Wegovy pill. Discover the medical realities of stopping weight loss medication.
8 min read
New “Trojan Horse” Drug Supercharges Weight Loss in Early Trials
A new hybrid molecule designed by Helmholtz Munich researchers acts as a Trojan horse to deliver metabolic compounds directly into cells, showing superior weight loss in mice compared to standard treatments.
8 min read
MOTS-C: A Peptide for Obesity Beyond GLP-1s?
While GLP-1 agonists have dominated weight loss discussions, a new peptide called MOTS-C is emerging with its own unique potential for tackling obesity and improving metabolic health. This article delves into what MOTS-C is, how it works, and its current research status.
7 min read
How GLP-1 Medications Can Affect Your Teeth
GLP-1 medications, known for their weight loss and blood sugar benefits, can also affect oral health. Learn about the common side effects and how to protect your teeth.
8 min read
Why I Lost Virtually No Weight on Wegovy and Mounjaro
Explore the real-world experience of a patient who spent thousands on GLP-1 injections without significant results, and learn what worked instead.
7 min read
Bitter Hops Extract Supplement for Weight Loss
A recent study suggests a bitter hops extract supplement, Amarasate, could aid fat loss and preserve muscle mass, offering a potential alternative or complementary approach to GLP-1 medications.
8 min read
GP's Verdict on GLP-1 Tablet Rollout: A Damp Squib?
A UK GP shares his observations on the limited uptake of new GLP-1 weight loss tablets, suggesting patient familiarity with injections and daily dosing challenges may be factors.
8 min read
Study Links Hormonal Birth Control Use to Higher Likelihood of Needing Weight Loss Injections
A recent Danish study suggests that women who have used hormonal birth control may be more likely to seek weight loss injections such as Wegovy and Ozempic. This research sheds light on a long-reported, yet often unproven, connection between contraceptives and weight changes.
7 min read
Eli Lilly Prepares FDA Run for ‘Triple-G’ Weight Loss Drug With Phase 3 Data
Eli Lilly has announced positive Phase 3 results for retatrutide, positioning the triple-agonist drug for an FDA filing in 2027 with substantial weight loss outcomes.
7 min read
Ozempic Lowers Calorie Intake For At Least A Year, Even If Hunger Returns, Trial Finds
A new 60-week clinical trial reveals that semaglutide continues to reduce calorie consumption significantly, even when subjective hunger sensations return to baseline levels.
7 min read
Meghan McCain Responds to 'Old and Ugly' Comments by Rejecting Ozempic
Meghan McCain has publicly pushed back against harsh online comments about her appearance, emphasizing her commitment to natural aging and rejecting the use of weight-loss medications like Ozempic.
6 min read
The Most Confronting Side Effect of Wegovy Weight Loss Wasn't Physical
While physical side effects of Wegovy are well-documented, one patient's experience highlights a profound, non-physical challenge: the shift in how society perceives and treats individuals after significant weight loss.
7 min read
Millions Losing Weight Using GLP-1s: How Do Drugs Affect Love Lives?
As millions turn to GLP-1 medications for weight loss, unexpected changes in romantic relationships and sexual desire are emerging. This article explores the psychological and physiological impacts on love lives.
6 min read
The Billion-Dollar Problem Limiting Access to Ozempic, Wegovy, and Zepbound
Despite clinical evidence highlighting the significant health benefits and cost-effectiveness of GLP-1 medications such as Ozempic, Wegovy, and Zepbound, many insurance plans continue to impose restrictions on patient access. This article delves into the financial and practical barriers, as well as the profound consequences for individuals seeking these transformative treatments.
7 min read
Oral GLP-1 Drugs May Quiet the Brain's Food Craving Circuit
New research suggests that oral GLP-1 medications, including those used for weight loss and diabetes, might work by influencing the brain's reward pathways, potentially reducing cravings for enjoyable foods and offering insights into treating substance use disorders.
8 min read
Katie Lee Biegel Shares Update on 'Incredibly Positive' GLP-1 Experience
Food Network personality Katie Lee Biegel opens up about her journey with GLP-1 medications, detailing her 'incredibly positive' experience with weight loss and enhanced well-being.
10 min read
Peptides, GLP-1s, and MAHA: A New Era in Wellness
The world of wellness is rapidly evolving, with groundbreaking advancements in peptide therapy and GLP-1 medications offering new avenues for health management and weight loss. This article delves into the science behind these innovations, explores the potential of 'MAHA' (Maximum Healthspan Aging), and discusses how individuals can navigate this exciting new frontier.
9 min read
Ozempic Face and Hair Loss: Evidence for GLP-1 Drug Side Effects
Weight-loss medications like Wegovy and Mounjaro have surged in popularity, leading to increased discussions about their side effects. This article delves into the scientific evidence for frequently reported concerns such as 'Ozempic face,' hair thinning, digestive problems, and eye conditions associated with GLP-1 agonists.
11 min read
Rosie O'Donnell: Mounjaro Changed My Life After Losing 30kg
Talk show host Rosie O'Donnell discusses her 30kg weight loss using Mounjaro, the subsequent skin concerns, and the mental health benefits of GLP-1 therapy.
6 min read
Novo Nordisk Sues Eli Lilly Over Which GLP-1 Sheds the Most Pounds
Novo Nordisk has filed a federal lawsuit against Eli Lilly, alleging deceptive advertising regarding the comparative weight loss efficacy of Zepbound and Wegovy. The dispute centers on dosage comparisons and clinical trial data interpretation.
8 min read
Fat Loss with GLP-1s, Muscle Loss Concerns: What Users Need to Know
GLP-1 medications are powerful tools for weight loss, but concerns are emerging about potential muscle mass loss. This article delves into what users need to know about preserving lean body mass and maintaining cardiorespiratory fitness alongside fat reduction.
7 min read
Eli Lilly to Seek FDA Approval for Obesity Drug Retatrutide
Eli Lilly announces plans to file for FDA approval of its triple-agonist obesity drug retatrutide in early 2027 following successful Phase 3 trial data.
8 min read
The New Drug Melting Body Fat From 38% To 22% — And The Side Effects Patients Are Ignoring
A detailed look at the case of Gary Anderton, who achieved significant weight loss using unregulated peptides, and the critical safety risks associated with this trend.
8 min read
AI Helps Stanford Scientists Discover Natural Ozempic Without the Usual Side Effects
Stanford Medicine researchers have identified a naturally occurring molecule that may suppress appetite and reduce body weight in a way that resembles semaglutide, the active ingredient in Ozempic.
8 min read
The Workforce Runs on Weight Loss Drugs? Employees on GLP-1s Take Fewer Sick Days
Employees on GLP-1 medications are taking significantly fewer sick days, leading to cost savings and improved productivity. A new study reveals the economic and health impacts of drugs like Ozempic and Wegovy on the workforce.
9 min read
China Adds Second GLP-1 Diabetes Drug to Essential Medicine List
China includes injectable semaglutide on its National Essential Drug List, improving access for diabetes patients while excluding obesity indications from the policy.
7 min read
Peptides: Lab Finds Issues in 30% of Vials as FDA Panel Considers Looser Rules
Peptides are rapidly gaining traction for various health and wellness claims, but a recent lab analysis revealed significant quality control issues in a substantial percentage of tested vials. As the FDA panel prepares to discuss potentially easing restrictions, understanding the risks and the science behind these compounds is crucial.
7 min read
Compounded Ozempic and Zepbound Still Widely Available After Shortages End
Despite the FDA declaring an end to drug shortages for popular weight loss medications, a new study finds compounded versions remain easily accessible. Understanding the safety implications and regulatory landscape is crucial for patient health.
8 min read
Novo Nordisk Sues Eli Lilly, Alleging Misleading Advertising of Obesity Drugs
Novo Nordisk has filed a lawsuit against Eli Lilly in New Jersey, claiming deceptive advertising regarding GLP-1 and dual-agonist weight loss medications.
7 min read
FDA Advisory Committee Votes to Lift Restrictions on Popular Wellness Peptide BPC-157
The FDA advisory committee recently voted to recommend lifting restrictions on BPC-157. This article details the vote, the science behind the peptide, and what it means for patient access.
7 min read
Study Links GLP-1 Medications To Rare Vision Issue
New research indicates a possible association between GLP-1 medications, commonly prescribed for type 2 diabetes and weight management, and a rare but serious vision issue. This article explores the study's findings, potential implications, and expert recommendations.
6 min read
Semaglutide Telehealth: From The Access Boom To Regulatory Reckoning
The rapid rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed obesity and diabetes care, generating billions in revenue for major manufacturers while creating unprecedented demand for weight management solutions. Telehealth platforms initially emerged as a critical access channel, offering convenient prescriptions and more affordable compounded versions during national shortages. Yet by 2025 and 2026, the sector faced a sharp pivot as FDA actions resolved shortages and curtailed large-scale compounding operations.
7 min read
The Workforce Runs on Weight Loss Drugs? Employees on GLP-1s Take Fewer Sick Days
A new study reveals significant reductions in long-term sick leave for workers taking GLP-1 medications, offering insights into workplace productivity and long-term health savings.
10 min read
Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising Claims in Legal Battle
Novo Nordisk has filed a lawsuit against Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising regarding GLP-1 weight loss medications.
7 min read
US Regulators Consider Controversial Peptides Backed by RFK Jr.
The US Food and Drug Administration is evaluating the use of seven peptides, increasingly marketed for wellness and medical conditions. This review comes amidst soaring popularity, celebrity endorsements, and significant debate over their safety and efficacy.
8 min read
Ozempic and Other GLP-1s Are Changing What Diners Order at Restaurants
A new study reveals how GLP-1 medications are reshaping restaurant ordering habits, from reduced spending to smaller portion preferences.
7 min read
Rosie O'Donnell: Mounjaro Changed My Life After Losing 30kg
Talk show host Rosie O'Donnell shares her candid experience with Mounjaro, detailing her 30kg weight loss, Type 2 diabetes management, and the physical consequences of rapid fat loss.
12 min read
Ozempic Maker Novo Nordisk Sues Eli Lilly Over 'Materially Misleading' Ads
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging deceptive advertising regarding weight-loss drugs. This legal battle highlights the intense competition between semaglutide and tirzepatide.
9 min read
GLP-1s for Teen Weight Loss: A New Treatment Trend?
GLP-1 medications are rapidly changing obesity care for teens and young adults, with a notable shift away from bariatric surgery. This article delves into the latest research, potential benefits, and important considerations for this emerging trend.
7 min read
Jim Cramer on Eli Lilly Amid Rival's GLP-1 Lawsuit
Jim Cramer weighs in on Eli Lilly's position in the GLP-1 market following a lawsuit from competitor Novo Nordisk, analyzing the situation for investors.
7 min read
Medicare's New GLP-1 Weight-Loss Drug Program: What to Know
Medicare is launching a new pilot program to increase access to GLP-1 medications for weight loss, offering a $50 monthly copay for eligible beneficiaries. This marks a significant step in covering obesity as a medical condition.
9 min read
Amy Schumer Shows Off Ongoing Weight Loss, Says C-Section Scar Makes Her a 'Warrior'
Comedian Amy Schumer discusses her 50-pound weight loss journey, Cushing syndrome diagnosis, and C-section recovery in a candid new update.
10 min read
Semaglutide Greenlit for MASH Liver Disease Treatment
The MHRA has granted conditional approval for semaglutide to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
7 min read
Anandita Sundar's 7-Year Weight Loss Journey and Body Shaming
Anandita Sundar opens up about her seven-year weight loss journey, highlighting the profound impact of body shaming on mental health and her commitment to prioritizing well-being over societal expectations.
7 min read
Plus-Size Swimsuit Model on Inclusivity Amidst GLP-1 Medications
Plus-size model Hunter McGrady shares her concerns about a perceived decline in fashion inclusivity, particularly in the context of the growing popularity of GLP-1 weight loss medications.
7 min read
Black-Market Peptide Surge Strains Needle and Syringe Programs
The rise of unregulated peptides for performance and image enhancement is placing significant pressure on vital harm reduction services, originally established to combat HIV. These programs are now facing increased demand and potential shortages of essential supplies.
7 min read
Which GLP-1 Works Best? New Meta-Study Puts Medications Head-to-Head
A comprehensive meta-analysis from the University of Georgia compares three major GLP-1 medications. Discover which drug offers the highest weight loss efficacy and what the data means for patients.
8 min read
Peptide Hype: Do They Live Up to the Claims for Skin and Wellness?
From skincare routines to GLP-1 weight loss medications, peptides are everywhere. But do they deliver on their promises for skin health, longevity, and recovery? This article delves into the science and the trend.
9 min read